Information  X 
Enter a valid email address

EPIC/TIDM matching '0QLR'

Date
Time Source
Company
Announcement
02 Apr 2020 3:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
28 Mar 2020 3:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
27 Mar 2020 1:02 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
  12:59 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
26 Mar 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis and Life Sciences Companies Commit Expertise and Assets to the Fight Against COVID-19 Pandemic alongside Bill & Melinda Gates Foundation
24 Mar 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
  6:13 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
20 Mar 2020 4:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
19 Mar 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
18 Mar 2020 9:01 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces NEJM publication of three pivotal trials showing durable and potent efficacy of inclisiran, an investigational first-in-class siRNA cholesterol-lowering therapy
02 Mar 2020 9:34 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz Resolves Generic Drug Antitrust Investigation in the U.S.
28 Feb 2020 12:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
24 Feb 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces FDA and EMA filing acceptance of ofatumumab, a novel B-cell therapy for patients with relapsing forms of multiple sclerosis (RMS)
17 Feb 2020 11:11 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
11 Feb 2020 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
31 Jan 2020 6:30 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines
29 Jan 2020 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019
20 Jan 2020 2:32 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
16 Jan 2020 8:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
06 Jan 2020 5:05 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran
  6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis completes tender offer for all outstanding shares of The Medicines Company
16 Dec 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
13 Dec 2019 12:03 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
09 Dec 2019 7:45 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
06 Dec 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
05 Dec 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day
  6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis tender offer for The Medicines Company commences
24 Nov 2019 8:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death
17 Nov 2019 3:45 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF
15 Nov 2019 8:06 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease
  11:27 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)
12 Nov 2019 6:25 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz presents real-world data showing effectiveness of Erelzi® (etanercept-szzs) in rheumatic disease treatment
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis
11 Nov 2019 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz announces agreement to acquire Aspen’s Japanese operations and associated assets, strengthening position in world’s third largest generics market
05 Nov 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz receives US FDA approval for long-acting oncology supportive care biosimilar Ziextenzo™ (pegfilgrastim-bmez)
01 Nov 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
30 Oct 2019 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces AVXS-101 intrathecal study update
24 Oct 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis
22 Oct 2019 6:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in US
08 Oct 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
02 Oct 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum
01 Oct 2019 3:00 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
30 Sep 2019 6:20 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
  6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
29 Sep 2019 3:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
  3:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients
19 Sep 2019 8:00 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
18 Sep 2019 1:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Positive results from Novartis five-year VERIFY study in type 2 diabetes demonstrate long-term clinical benefits of early combination treatment with Galvus® and metformin
17 Sep 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
13 Sep 2019 1:15 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
03 Sep 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine
02 Sep 2019 7:30 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
01 Sep 2019 1:30 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint
30 Aug 2019 6:15 am GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies
09 Aug 2019 8:46 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Sandoz will appeal District Court of New Jersey ruling in biosimilar Erelzi® (etanercept-szzs) US patent case
06 Aug 2019 11:08 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis stands behind Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of children less than 2 years of age with spinal muscular atrophy
31 Jul 2019 3:05 pm GNW Factsheet NOVARTIS AG CHF0.50(REGD) (0QLR) Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
29 Jul 2019 6:00 am GNW Factsheet Novartis International AG (0QLR) Novartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)
26 Jul 2019 1:06 pm GNW Factsheet Novartis International AG (0QLR) Novartis receives positive CHMP opinion for Lucentis® treatment in preterm infants with retinopathy of prematurity (ROP), a disease causing visual impairment and blindness


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t